Due to high tumor mutation burden (TMB) and great prevalence for PD-L1 and 2 in PSC,[18–21] immunotherapy (immune checkpoint inhibitors) shows encouragingly enduring efficacy in PSC patients (Table 2).[22–25] Furthermore, the registered trials of immunotherapy in PSC is listed in Table 3. Here, CD274 is linked to neoplasm.